HPC HOLDINGS (01742) releases interim results, with a profit of SGD 31.342 million for the period, an increase of 4766.77% compared to the previous year.
HPC Holdings (01742) released its interim results for the six months ending on April 30, 2025.
HPC Holdings (01742) released its interim results for the six months ending on April 30, 2025. The revenue was SGD 118 million, an increase of 35.43% compared to the previous year; the net profit for the period was SGD 31.342 million, an increase of 4766.77% compared to the previous year; and the basic earnings per share was SGD 1.96 cents.
Related Articles

Huayu Pharmaceutical (688553.SH): Injection HY05350 has obtained the drug clinical trial approval notice.

On June 30, LEON INSPECTION (01586) spent 449,600 Hong Kong dollars to repurchase 180,000 shares.

COSMO LADY(02298): Wu Xiaoli appointed as a member of the nomination committee.
Huayu Pharmaceutical (688553.SH): Injection HY05350 has obtained the drug clinical trial approval notice.

On June 30, LEON INSPECTION (01586) spent 449,600 Hong Kong dollars to repurchase 180,000 shares.

COSMO LADY(02298): Wu Xiaoli appointed as a member of the nomination committee.

RECOMMEND

Trump Signals End to Trade Talks, Vows to Impose Tariffs Unilaterally Ahead of July 9 Deadline
30/06/2025

One License Unlocks HKD 23.4 Billion Surge: Unpacking Hong Kong’s Ambitions as a Global Virtual Asset Hub
30/06/2025

16 Companies Submit IPO Applications in One Day; Hong Kong IPO Fundraising Hits Three-Year High
30/06/2025